Global Pompe Disease Treatment Market Research Report Forecast to 2030

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,950	123 Pages	Market Research Future	April, 2023	RESFT17886090

Best Price Guarantee
Price	from $4,950
Length	123 Pages
Publisher	Market Research Future
Published Date	April, 2023
SKU	RESFT17886090

Global Pompe Disease Treatment Market Research Report Forecast to 2030

Pompe disease treatment, Market Forecast till 2030 Market Overview The global market for pompe disease treatment is expected to increase at a large over the forecast period of 2022-2030. This is a rare and fatal disorder that causes degeneration of brain cells, leading to tremors, seizures, and cognitive impairment. The treatment market for Pompe disease has been growing in recent years, with a prevalence of about 1 in 200,000 people in the USA and an annual incidence rate of about 1 case per 800,000 people. The treatment market includes both direct-to-consumer options such as stem cell transplantation, bone marrow transplantation, chemotherapy, and immunotherapy, as well as healthcare providers such as academic medical centers and private practices. The market for Pompe disease treatment is expected to grow in the coming years due to the increasing prevalence of the disease, and the availability of new treatment options. The growing awareness about the disease and the availability of new therapies, such as enzyme replacement therapy (ERT), is also expected to drive the market growth. ERT is the most commonly used treatment for Pompe disease and is considered to be the standard of care. However, there are also other treatment options available, such as gene therapy and substrate reduction therapy (SRT). These treatments are still in the early stages of development, but are showing promising results in clinical trials. The Pompe disease treatment is expected to benefit from rising number of clinical trials for new therapies. This is expected to lead to the development of more effective treatments for the disease in the future. Overall, the market for Pompe disease treatment is expected to grow in the coming years due to the increasing prevalence of the disease, the availability of new treatment options, and the growing awareness about the disease. The market is also driven by the increasing number of patients being diagnosed with Pompe disease, and the growing number of clinical trials for new therapies. This is expected to lead to the development of more effective treatments for the disease in the future. Segment Overview The Type, treatment type, end user, and regional segmentation have been used to segment the market of the global Pompe Disease treatment market. The market has been segmented into three main categories based on the type of Pompe disease: Non-Classic Infantile-Onset Pompe Disease, Late-Onset Pompe Disease, and Classic Infantile-Onset Pompe Disease. The Therapy type segment has been split The Treatment Types section has been divided into Gene Therapy, Enzyme Replacement Therapy, and Others.urcated into Research and Academic Institutes, Hospitals and Clinics Regional Analysis North America is expected to dominate the market and hold the major share due to the presence of advanced healthcare infrastructure and the high prevalence of Pompe disease in the region. The availability of reimbursement policies, increased awareness about Pompe disease, and the presence of major market players in the region also contribute to the market growth in North America. In Europe, countries such as Italy, Germany, and France are expected to show a significant progress due to the increasing prevalence of the disease and the availability of advanced healthcare infrastructure. Major Players Oxyrane (UK), Valerion Therapeutics (US), AVROBIO, Inc. (US), Audentes Therapeutics (US), Amicus Therapeutics, Inc (US), Sanofi (France), CENTOGENE AG (UK) are some of the affluent contenders holding sizeable pompe disease treatment market share. COVID 19 Impacts The pandemic caused by COVID-19 has affected the supply chain and the production of medical products for Pompe disease. The market may face disruption due to a lack of attendance of human labour at work and in factories. However, there is a silver lining. Just like any other market, advanced technology has taken place instead of human labour. Though it may need human interventions from time to time, it is indeed scarce. The government of various nations are running vaccine drives. The initial months of the COVID-19 pandemic saw a decline in production of the market. However, the Pompe Disease Treatment Market has paced up production.

Companies Mentioned
Oxyrane (UK)
Valerion Therapeutics (US)
AVROBIO
Inc. (US)
Audentes Therapeutics (US)
Amicus Therapeutics
Inc (US)
Sanofi (France)
CENTOGENE AG (UK)

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.

1 Executive Summary
2 Market Introduction: 2.1 Scope Of The Study 13; 2.2 Research Objective 13; 2.3 Market Structure 13; 2.4 Assumptions & Limitations 14
3 Research Methodology: 3.1 Data Mining 15; 3.2 Secondary Research 16; 3.3 Primary Research 17; 3.4 Breakdown Of Primary Respondents 18; 3.5 Forecasting Techniques 19; 3.6 Research Methodology For Market Size Estimation 20; 3.6.1 Bottom-up Approach 20; 3.6.2 Top-down Approach 21; 3.7 Data Triangulation 21; 3.8 Validation 21
4 Market Dynamics: 4.1 Overview 22; 4.2 Drivers 23; 4.2.1 Increasing Government Initiatives 23; 4.2.2 Rising R&D Activities By Manufacturers 23; 4.3 Restraints 24; 4.3.1 High Cost Of Treatment 24; 4.4 Opportunities 25; 4.4.1 Emergence Of Immunotherapeutic Approaches 25; 4.5 Challenges 25
5 Market Factor Analysis: 5.1 Value Chain Analysis 26; 5.1.1 R&D And Designing 27; 5.1.2 Manufacturing 27; 5.1.3 Distribution & Sales 27; 5.1.4 Post-sales Services 27; 5.2 Porter’s Five Forces Model 28; 5.2.1 Bargaining Power Of Suppliers 29; 5.2.2 Bargaining Power Of Buyers 29; 5.2.3 Threat Of New Entrants 29; 5.2.4 Threat Of Substitutes 29; 5.2.5 Intensity Of Rivalry 29
6 Pompe Disease Treatment Market, By Type: 6.1 Overview 30; 6.2 Late-onset Pompe Disease 31; 6.3 Classic Infantile-onset Pompe Disease 31; 6.4 Non-classic Infantile-onset Pompe Disease 32
7 Pompe Disease Treatment Market, By Therapy: 7.1 Overview 33; 7.2 Enzyme Replacement Therapy (Ert) 34; 7.3 Gene Therapy 34; 7.4 Others 34
8 Pompe Disease Treatment Market, By End User: 8.1 Overview 35; 8.2 Hospitals & Clinics 36; 8.3 Research & Academic Institutes 36
9 Global Pompe Disease Treatment Market, By Region: 9.1 Overview 37; 9.2 Americas 39; Pompe Disease Treatment Market, By Type; Pompe Disease Treatment Market, By Therapy; Pompe Disease Treatment Market, By End User; 9.2.1 North America 40; Pompe Disease Treatment Market, By Type; Pompe Disease Treatment Market, By Therapy; Pompe Disease Treatment Market, By End User; 9.2.1.1 Us 42; Pompe Disease Treatment Market, By Type; Pompe Disease Treatment Market, By Therapy; Pompe Disease Treatment Market, By End User; 9.2.1.2 Canada 43; Pompe Disease Treatment Market, By Type; Pompe Disease Treatment Market, By Therapy; Pompe Disease Treatment Market, By End User; 9.2.2 South America 44; Pompe Disease Treatment Market, By Type; Pompe Disease Treatment Market, By Therapy; Pompe Disease Treatment Market, By End User; 9.3 Europe 46; Pompe Disease Treatment Market, By Type; Pompe Disease Treatment Market, By Therapy; Pompe Disease Treatment Market, By End User; 9.3.1 Germany 48; Pompe Disease Treatment Market, By Type; Pompe Disease Treatment Market, By Therapy; Pompe Disease Treatment Market, By End User; 9.3.2 France 49; Pompe Disease Treatment Market, By Type; Pompe Disease Treatment Market, By Therapy; Pompe Disease Treatment Market, By End User; 9.3.3 Uk 50; Pompe Disease Treatment Market, By Type; Pompe Disease Treatment Market, By Therapy; Pompe Disease Treatment Market, By End User; 9.3.4 Italy 51; Pompe Disease Treatment Market, By Type; Pompe Disease Treatment Market, By Therapy; Pompe Disease Treatment Market, By End User; 9.3.5 Spain 52; Pompe Disease Treatment Market, By Type; Pompe Disease Treatment Market, By Therapy; Pompe Disease Treatment Market, By End User; 9.3.6 Rest Of Europe 53; Pompe Disease Treatment Market, By Type; Pompe Disease Treatment Market, By Therapy; Pompe Disease Treatment Market, By End User; 9.4 Asia-pacific 54; Pompe Disease Treatment Market, By Type; Pompe Disease Treatment Market, By Therapy; Pompe Disease Treatment Market, By End User; 9.4.1 China 56; Pompe Disease Treatment Market, By Type; Pompe Disease Treatment Market, By Therapy; Pompe Disease Treatment Market, By End User; 9.4.2 Japan 57; Pompe Disease Treatment Market, By Type; Pompe Disease Treatment Market, By Therapy; Pompe Disease Treatment Market, By End User; 9.4.3 India 58; Pompe Disease Treatment Market, By Type; Pompe Disease Treatment Market, By Therapy; Pompe Disease Treatment Market, By End User; 9.4.4 South Korea 59; Pompe Disease Treatment Market, By Type; Pompe Disease Treatment Market, By Therapy; Pompe Disease Treatment Market, By End User; 9.4.5 Australia 60; Pompe Disease Treatment Market, By Type; Pompe Disease Treatment Market, By Therapy; Pompe Disease Treatment Market, By End User; 9.4.6 Rest Of Asia-pacific 61; Pompe Disease Treatment Market, By Type; Pompe Disease Treatment Market, By Therapy; Pompe Disease Treatment Market, By End User; 9.5 Middle East & Africa 62; Pompe Disease Treatment Market, By Type; Pompe Disease Treatment Market, By Therapy; Pompe Disease Treatment Market, By End User; 9.5.1 Middle East 63; Pompe Disease Treatment Market, By Type; Pompe Disease Treatment Market, By Therapy; Pompe Disease Treatment Market, By End User; 9.5.2 Africa 64; Pompe Disease Treatment Market, By Type; Pompe Disease Treatment Market, By Therapy; Pompe Disease Treatment Market, By End User
10 Competitive Landscape: 10.1 Overview 66; 10.2 Major Players In The Global Pompe Disease Treatment Market 66; 10.3 Competitive Benchmarking 67; 10.4 Competitor Dashboard 68; 10.5 Major Growth Strategy In The Global Pompe Disease Treatment Market 69; 10.6 The Leading Player In Terms Of Number Of Developments In Global Pompe Disease Treatment; Market 69; 10.7 Key Developments & Growth Strategies 70; 10.7.1 Expansion 70; 10.7.2 Announcement 71; 10.7.3 Patent 71; 10.7.4 Developments 71; 10.7.5 Definitive Agreement 71
11 Company Profiles: 11.1 Amicus Therapeutics, Inc 72; 11.1.1 Company Overview 72; 11.1.2 Financial Overview 72; 11.1.3 Products/Services Offered 72; 11.1.4 Key Developments 73; 11.1.5 Swot Analysis 73; 11.1.6 Key Strategies 73; 11.2 Sanofi 74; 11.2.1 Company Overview 74; 11.2.2 Financial Overview 74; 11.2.3 Products/Services Offered 75; 11.2.4 Key Developments 75; 11.2.5 Swot Analysis 76; 11.2.6 Key Strategies 76; 11.3 Audentes Therapeutics 77; 11.3.1 Company Overview 77; 11.3.2 Financial Overview 77; 11.3.3 Products/Services Offered 77; 11.3.4 Key Developments 78; 11.3.5 Swot Analysis 78; 11.3.6 Key Strategies 78; 11.4 Oxyrane 79; 11.4.1 Company Overview 79; 11.4.2 Financial Overview 79; 11.4.3 Products/Services Offered 79; 11.4.4 Key Developments 79; 11.4.5 Swot Analysis 80; 11.4.6 Key Strategies 80; 11.5 Valerion Therapeutics 81; 11.5.1 Company Overview 81; 11.5.2 Financial Overview 81; 11.5.3 Products/Services Offered 81; 11.5.4 Key Developments 81; 11.5.5 Swot Analysis 82; 11.5.6 Key Strategies 82; 11.6 Avrobio, Inc. 83; 11.6.1 Company Overview 83; 11.6.2 Financial Overview 83; 11.6.3 Products/Services Offered 84; 11.6.4 Key Developments 84; 11.6.5 Swot Analysis 84; 11.6.6 Key Strategies 84; 11.7 Centogene Ag 85; 11.7.1 Company Overview 85; 11.7.2 Financial Overview 85; 11.7.3 Products/Services Offered 85; 11.7.4 Key Developments 85; 11.7.5 Swot Analysis 86; 11.7.6 Key Strategies 86
12 Appendix: 12.1 References 87; 12.2 Related Reports 87
List Of Tables: Table 1 List Of Assumptions 14; Table 2 Primary Interviews And Information Gathering Process 17; Table 3 Global Pompe Disease Treatment Market, By Type 2016–2030 (Usd Million) 30; Table 4 Global Pompe Disease Treatment Market, For Late-onset Pompe Disease, By Region 2016–2030 (Usd Million) 31; Table 5 Global Pompe Disease Treatment Market, For Classic Infantile-onset Pompe Disease, By Region 2016–2030; (Usd Million) 31; Table 6 Global Pompe Disease Treatment Market, For Non-classic Infantile-onset Pompe Disease, By Region 2016–2030; (Usd Million) 32; Table 7 Global Pompe Disease Treatment Market, By Therapy 2016–2030 (Usd Million) 33; Table 8 Global Pompe Disease Treatment Market, For Enzyme Replacement Therapy (Ert), By Region 2016–2030; (Usd Million) 34; Table 9 Global Pompe Disease Treatment Market, For Gene Therapy, By Region 2016–2030 (Usd Million) 34; Table 10 Global Pompe Disease Treatment Market, By End User 2016–2030 (Usd Million) 35; Table 11 Global Pompe Disease Treatment Market, For Hospitals & Clinics, By Region 2016–2030 (Usd Million) 36; Table 12 Global Pompe Disease Treatment Market, For Research & Academic Institutes, By Region 2016–2030; (Usd Million) 36; Table 13 Global Pompe Disease Treatment Market, By Region 2016–2030 (Usd Million) 37; Table 14 Americas: Pompe Disease Treatment Market, By Region 2016–2030 (Usd Million) 39; Table 15 Americas: Pompe Disease Treatment Market, By Type 2016–2030 (Usd Million) 39; Table 16 Americas: Pompe Disease Treatment Market, By Therapy 2016–2030 (Usd Million) 40; Table 17 Americas: Pompe Disease Treatment Market, By End User 2016–2030 (Usd Million) 40; Table 18 North America: Pompe Disease Treatment Market, By Country 2016–2030 (Usd Million) 40; Table 19 North America: Pompe Disease Treatment Market, By Type 2016–2030 (Usd Million) 41; Table 20 North America: Pompe Disease Treatment Market, By Therapy 2016–2030 (Usd Million) 41; Table 21 North America: Pompe Disease Treatment Market, By End User 2016–2030 (Usd Million) 42; Table 22 Us: Pompe Disease Treatment Market, By Type 2016–2030 (Usd Million) 42; Table 23 Us: Pompe Disease Treatment Market, By Therapy 2016–2030 (Usd Million) 42; Table 24 Us: Pompe Disease Treatment Market, By End User 2016–2030 (Usd Million) 43; Table 25 Canada: Pompe Disease Treatment Market, By Type 2016–2030 (Usd Million) 43; Table 26 Canada: Pompe Disease Treatment Market, By Therapy 2016–2030 (Usd Million) 43; Table 27 Canada: Pompe Disease Treatment Market, By End User 2016–2030 (Usd Million) 44; Table 28 South America: Pompe Disease Treatment Market, By Type 2016–2030 (Usd Million) 44; Table 29 South America: Pompe Disease Treatment Market, By Therapy 2016–2030 (Usd Million) 44; Table 30 South America: Pompe Disease Treatment Market, By End User 2016–2030 (Usd Million) 45; Table 31 Europe: Pompe Disease Treatment Market, By Country 2016–2030 (Usd Million) 46; Table 32 Europe: Pompe Disease Treatment Market, By Type 2016–2030 (Usd Million) 47; Table 33 Europe: Pompe Disease Treatment Market, By Therapy 2016–2030 (Usd Million) 47; Table 34 Europe: Pompe Disease Treatment Market, By End User 2016–2030 (Usd Million) 47; Table 35 Germany: Pompe Disease Treatment Market, By Type 2016–2030 (Usd Million) 48; Table 36 Germany: Pompe Disease Treatment Market, By Therapy 2016–2030 (Usd Million) 48; Table 37 Germany: Pompe Disease Treatment Market, By End User 2016–2030 (Usd Million) 48; Table 38 France: Pompe Disease Treatment Market, By Type 2016–2030 (Usd Million) 49; Table 39 France: Pompe Disease Treatment Market, By Therapy 2016–2030 (Usd Million) 49; Table 40 France: Pompe Disease Treatment Market, By End User 2016–2030 (Usd Million) 49; Table 41 Uk: Pompe Disease Treatment Market, By Type 2016–2030 (Usd Million) 50; Table 42 Uk: Pompe Disease Treatment Market, By Therapy 2016–2030 (Usd Million) 50; Table 43 Uk: Pompe Disease Treatment Market, By End User 2016–2030 (Usd Million) 50; Table 44 Italy: Pompe Disease Treatment Market, By Type 2016–2030 (Usd Million) 51; Table 45 Italy: Pompe Disease Treatment Market, By Therapy 2016–2030 (Usd Million) 51; Table 46 Italy: Pompe Disease Treatment Market, By End User 2016–2030 (Usd Million) 51; Table 47 Spain: Pompe Disease Treatment Market, By Type 2016–2030 (Usd Million) 52; Table 48 Spain: Pompe Disease Treatment Market, By Therapy 2016–2030 (Usd Million) 52; Table 49 Spain: Pompe Disease Treatment Market, By End User 2016–2030 (Usd Million) 52; Table 50 Rest Of Europe: Pompe Disease Treatment Market, By Type 2016–2030 (Usd Million) 53; Table 51 Rest Of Europe: Pompe Disease Treatment Market, By Therapy 2016–2030 (Usd Million) 53; Table 52 Rest Of Europe: Pompe Disease Treatment Market, By End User 2016–2030 (Usd Million) 53; Table 53 Asia-pacific: Pompe Disease Treatment Market, By Country 2016–2030 (Usd Million) 54; Table 54 Asia-pacific: Pompe Disease Treatment Market, By Type 2016–2030 (Usd Million) 55; Table 55 Asia-pacific: Pompe Disease Treatment Market, By Therapy 2016–2030 (Usd Million) 55; Table 56 Asia-pacific: Pompe Disease Treatment Market, By End User 2016–2030 (Usd Million) 55; Table 57 China: Pompe Disease Treatment Market, By Type 2016–2030 (Usd Million) 56; Table 58 China: Pompe Disease Treatment Market, By Therapy 2016–2030 (Usd Million) 56; Table 59 China: Pompe Disease Treatment Market, By End User 2016–2030 (Usd Million) 56; Table 60 Japan: Pompe Disease Treatment Market, By Type 2016–2030 (Usd Million) 57; Table 61 Japan: Pompe Disease Treatment Market, By Therapy 2016–2030 (Usd Million) 57; Table 62 Japan: Pompe Disease Treatment Market, By End User 2016–2030 (Usd Million) 57; Table 63 India: Pompe Disease Treatment Market, By Type 2016–2030 (Usd Million) 58; Table 64 India: Pompe Disease Treatment Market, By Therapy 2016–2030 (Usd Million) 58; Table 65 India: Pompe Disease Treatment Market, By End User 2016–2030 (Usd Million) 58; Table 66 South Korea: Pompe Disease Treatment Market, By Type 2016–2030 (Usd Million) 59; Table 67 South Korea: Pompe Disease Treatment Market, By Therapy 2016–2030 (Usd Million) 59; Table 68 South Korea: Pompe Disease Treatment Market, By End User 2016–2030 (Usd Million) 59; Table 69 Australia: Pompe Disease Treatment Market, By Type 2016–2030 (Usd Million) 60; Table 70 Australia: Pompe Disease Treatment Market, By Therapy 2016–2030 (Usd Million) 60; Table 71 Australia: Pompe Disease Treatment Market, By End User 2016–2030 (Usd Million) 60; Table 72 Rest Of Asia-pacific: Pompe Disease Treatment Market, By Type 2016–2030 (Usd Million) 61; Table 73 Rest Of Asia-pacific: Pompe Disease Treatment Market, By Therapy 2016–2030 (Usd Million) 61; Table 74 Rest Of Asia-pacific: Pompe Disease Treatment Market, By End User 2016–2030 (Usd Million) 61; Table 75 Middle East & Africa: Pompe Disease Treatment Market, By Region 2016–2030 (Usd Million) 62; Table 76 Middle East & Africa: Pompe Disease Treatment Market, By Type 2016–2030 (Usd Million) 62; Table 77 Middle East & Africa: Pompe Disease Treatment Market, By Therapy 2016–2030 (Usd Million) 63; Table 78 Middle East & Africa: Pompe Disease Treatment Market, By End User 2016–2030 (Usd Million) 63; Table 79 Middle East: Pompe Disease Treatment Market, By Type 2016–2030 (Usd Million) 63; Table 80 Middle East: Pompe Disease Treatment Market, By Therapy 2016–2030 (Usd Million) 64; Table 81 Middle East: Pompe Disease Treatment Market, By End User 2016–2030 (Usd Million) 64; Table 82 Africa: Pompe Disease Treatment Market, By Type 2016–2030 (Usd Million) 64; Table 83 Africa: Pompe Disease Treatment Market, By Therapy 2016–2030 (Usd Million) 65; Table 84 Africa: Pompe Disease Treatment Market, By End User 2016–2030 (Usd Million) 65; Table 85 Major Players In The Global Pompe Disease Treatment Market 66; Table 86 Competitor Dashboard: Global Pompe Disease Treatment Market 68; Table 87 The Most Active Player In The Global Pompe Disease Treatment Market 69; Table 88 Expansion 70; Table 89 Announcement 71; Table 90 Patent 71; Table 91 Developments 71; Table 92 Definitive Agreement 71; Table 93 Amicus Therapeutics, Inc: Financial Information 72; Table 94 Amicus Therapeutics, Inc: Products/Services Offered 72; Table 95 Amicus Therapeutics, Inc: Key Developments 73; Table 96 Sanofi: Financial Information 74; Table 97 Sanofi : Products/Services Offered 75; Table 98 Sanofi : Key Developments 75; Table 99 Audentes Therapeutics: Financial Information 77; Table 100 Audentes Therapeutics : Products/Services Offered 77; Table 101 Audentes Therapeutics: Key Developments 78; Table 102 Oxyrane : Products/Services Offered 79; Table 103 Valerion Therapeutics : Products/Services Offered 81; Table 104 Valerion Therapeutics: Key Developments 81; Table 105 Avrobio, Inc.: Financial Information 83; Table 106 Avrobio, Inc.: Products/Services Offered 84; Table 107 Centogene Ag : Products/Services Offered 85; Table 108 Centogene Ag : Key Developments 85
Llist Of Figures: Figure 1 Market Synopsis 12; Figure 2 Global Pompe Disease Treatment Market: Structure 13; Figure 3 Bottom-up And Top-down Approaches 20; Figure 4 Market Dynamics: Analysis Of Global Pompe Disease Treatment Market 22; Figure 5 Driver Impact Analysis 24; Figure 6 Restraint Impact Analysis 24; Figure 7 Value Chain: Global Pompe Disease Treatment Market 26; Figure 8 Porter’s Five Forces Analysis: Global Pompe Disease Treatment Market 28; Figure 9 Global Pompe Disease Treatment Market, By Type 2018 & 2030 (Usd Million) 30; Figure 10 Global Pompe Disease Treatment Market, By Therapy 2018 & 2030 (Usd Million) 33; Figure 11 Global Pompe Disease Treatment Market, By End User 2018 & 2030 (Usd Million) 35; Figure 12 Global Pompe Disease Treatment Market Share, By Region 2018 (%) 38; Figure 13 Americas: Pompe Disease Treatment Market Share, By Region 2018 (%) 39; Figure 14 North America: Pompe Disease Treatment Market Share, By Country 2018 (%) 41; Figure 15 Europe: Pompe Disease Treatment Market Share, By Country 2018 (%) 46; Figure 16 Asia-pacific: Pompe Disease Treatment Market Share, Bycountry/ Region 2018 (%) 54; Figure 17 Middle East & Africa: Pompe Disease Treatment Market Share, By Region 2018 (%) 62; Figure 18 Benchmarking Of Major Competitors 67; Figure 19 Major Strategy Adopted By Key Players In The Pompe Disease Treatment Market 69; Figure 20 Global Pompe Disease Treatment Market, Key Developments & Growth Strategies (%) 70; Figure 21 Amicus Therapeutics, Inc : Swot Analysis 73; Figure 22 Sanofi : Swot Analysis 76; Figure 23 Audentes Therapeutics : Swot Analysis 78; Figure 24 Oxyrane : Swot Analysis 80; Figure 25 Valerion Therapeutics : Swot Analysis 82; Figure 26 Avrobio, Inc.: Swot Analysis 84; Figure 27 Centogene Ag : Swot Analysis